These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia. Mulligan SP; Opat S; Marlton P; Kuss B; Gerungan P; Puig A; McGeachie M; Tam CS Br J Haematol; 2022 Aug; 198(4):790-793. PubMed ID: 35702012 [No Abstract] [Full Text] [Related]
47. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Mato AR; Nabhan C; Thompson MC; Lamanna N; Brander DM; Hill B; Howlett C; Skarbnik A; Cheson BD; Zent C; Pu J; Kiselev P; Goy A; Claxton D; Isaac K; Kennard KH; Timlin C; Landsburg D; Winter A; Nasta SD; Bachow SH; Schuster SJ; Dorsey C; Svoboda J; Barr P; Ujjani CS Haematologica; 2018 May; 103(5):874-879. PubMed ID: 29419429 [TBL] [Abstract][Full Text] [Related]
48. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258 [TBL] [Abstract][Full Text] [Related]
49. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. O'Brien SM; Byrd JC; Hillmen P; Coutre S; Brown JR; Barr PM; Barrientos JC; Devereux S; Robak T; Reddy NM; Kipps TJ; Tedeschi A; Cymbalista F; Ghia P; Chang S; Ninomoto J; James DF; Burger JA Am J Hematol; 2019 May; 94(5):554-562. PubMed ID: 30767298 [TBL] [Abstract][Full Text] [Related]
50. Atypical Painful Purpuric Cutaneous Nodules With Ibrutinib. Marcaillou M; Stéphanie D; Marion B; Julien S; Christophe B Am J Dermatopathol; 2020 Dec; 42(12):1012-1014. PubMed ID: 32675466 [No Abstract] [Full Text] [Related]
51. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803 [TBL] [Abstract][Full Text] [Related]
52. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Hampel PJ; Ding W; Call TG; Rabe KG; Kenderian SS; Witzig TE; Muchtar E; Leis JF; Chanan-Khan AA; Koehler AB; Fonder AL; Schwager SM; Slager SL; Shanafelt TD; Kay NE; Parikh SA Leuk Lymphoma; 2019 Nov; 60(11):2712-2719. PubMed ID: 31014142 [TBL] [Abstract][Full Text] [Related]
53. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985 [TBL] [Abstract][Full Text] [Related]
54. Ibrutinib for Chronic Lymphocytic Leukemia with Ahn IE; Tian X; Wiestner A N Engl J Med; 2020 Jul; 383(5):498-500. PubMed ID: 32726539 [No Abstract] [Full Text] [Related]
55. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Lipsky AH; Farooqui MZ; Tian X; Martyr S; Cullinane AM; Nghiem K; Sun C; Valdez J; Niemann CU; Herman SE; Saba N; Soto S; Marti G; Uzel G; Holland SM; Lozier JN; Wiestner A Haematologica; 2015 Dec; 100(12):1571-8. PubMed ID: 26430171 [TBL] [Abstract][Full Text] [Related]
56. Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. Pula B; Iskierka-Jazdzewska E; Dlugosz-Danecka M; Szymczyk A; Hus M; Szeremet A; Drozd-Sokolowska J; Waszczuk-Gajda A; Zaucha JM; Holojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Osowiecki M; Knopinska-Posluszny W; Dudzinski M; Zawirska D; Subocz E; Halka J; Pluta A; Wichary R; Kumiega B; Budziszewska BK; Jurczak W; Lech-Maranda E; Giannopoulos K; Robak T; Jamroziak K Anticancer Res; 2020 Jul; 40(7):4059-4066. PubMed ID: 32620653 [TBL] [Abstract][Full Text] [Related]
57. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Brown JR; Barrientos JC; Barr PM; Flinn IW; Burger JA; Tran A; Clow F; James DF; Graef T; Friedberg JW; Rai K; O'Brien S Blood; 2015 May; 125(19):2915-22. PubMed ID: 25755291 [TBL] [Abstract][Full Text] [Related]
58. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre. Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654 [TBL] [Abstract][Full Text] [Related]
59. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG). Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135 [TBL] [Abstract][Full Text] [Related]